abstract: BACKGROUND: This study aims to investigate @entity460 -binding myeloid-related protein (MRP)-8/14 in the saliva and serum of individuals with @entity2521 and periodontally healthy individuals for the assessment of its role in the pathogenesis and clinical diagnosis of @entity2521 . METHODS: This cross-sectional study includes 56 @entity1 with @entity2521 and 44 periodontally healthy individuals. Saliva and serum were collected for the detection of @entity29415 /14 and @entity460 levels. Periodontopathic bacteria were determined by polymerase chain reaction in saliva. Correlations between salivary and serum @entity29415 /14 levels and clinical parameters, bacteria, and @entity460 were analyzed with Pearson correlation in a multiple regression model. @entity29415 /14 levels were documented with receiver operating characteristic (ROC) curves. RESULTS: Compared with healthy individuals, @entity29415 /14 levels were significantly higher in both the saliva and serum of @entity1 with @entity2521 , but @entity460 was increased only in saliva. A high diagnostic potential of salivary @entity29415 /14 was detected for @entity2521 (ROC = 0.86). Salivary @entity29415 /14 levels correlated significantly with the presence of the periodontopathogen @entity14148 , as well as with the clinical parameters of @entity2521 . CONCLUSION: @entity29415 /14 in saliva might be a potential diagnostic parameter for periodontal disease.

title: Comparative Analysis of XXXX -Binding Myeloid-Related Protein-8/14 in Saliva and Serum of @entity1 With @entity2521 and Healthy Individuals.

answer: @entity460 :: (MESH:D002118,Chemical) :: ['Calcium']


abstract: BACKGROUND: This study aims to investigate @entity460 -binding myeloid-related protein (MRP)-8/14 in the saliva and serum of individuals with @entity2521 and periodontally healthy individuals for the assessment of its role in the pathogenesis and clinical diagnosis of @entity2521 . METHODS: This cross-sectional study includes 56 @entity1 with @entity2521 and 44 periodontally healthy individuals. Saliva and serum were collected for the detection of @entity29415 /14 and @entity460 levels. Periodontopathic bacteria were determined by polymerase chain reaction in saliva. Correlations between salivary and serum @entity29415 /14 levels and clinical parameters, bacteria, and @entity460 were analyzed with Pearson correlation in a multiple regression model. @entity29415 /14 levels were documented with receiver operating characteristic (ROC) curves. RESULTS: Compared with healthy individuals, @entity29415 /14 levels were significantly higher in both the saliva and serum of @entity1 with @entity2521 , but @entity460 was increased only in saliva. A high diagnostic potential of salivary @entity29415 /14 was detected for @entity2521 (ROC = 0.86). Salivary @entity29415 /14 levels correlated significantly with the presence of the periodontopathogen @entity14148 , as well as with the clinical parameters of @entity2521 . CONCLUSION: @entity29415 /14 in saliva might be a potential diagnostic parameter for periodontal disease.

title: Comparative Analysis of @entity460 -Binding Myeloid-Related Protein-8/14 in Saliva and Serum of XXXX With @entity2521 and Healthy Individuals.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity14148 :: ('158', 'Species') :: ['Treponema denticola']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: Herbal agents such as Aloe vera (AV) have been used in medical and dental therapy for thousands of years. AV has anti-inflammatory, antioxidant, antimicrobial, hypoglycemic, healing-promoting, and immune-boosting properties. This study aims to investigate the clinical effectiveness of locally delivered AV gel used as an adjunct to scaling and root planing (SRP) in the treatment of @entity1 with @entity6 ( @entity6 ) and @entity7278 ( @entity7278 ). METHODS: Sixty @entity1 with @entity92 ( @entity92 ) >= 5 mm and clinical attachment level (CAL) >= 3 mm were randomly divided into two groups. All @entity1 underwent SRP. Placebo gel was locally delivered to group 1 and AV gel to group 2. Full-mouth plaque index (PI), modified sulcus bleeding index (mSBI), @entity92 , and CAL were recorded at baseline and 3 and 6 months. RESULTS: @entity1 in group 2 showed significantly greater mean reductions in PI, mSBI, and @entity92 and mean gain in CAL compared with those in group 1 from baseline to 3 months. Gain in CAL was significantly greater in group 2 at all time intervals versus group 1. CONCLUSION: Adjunctive use of locally delivered AV gel, in comparison to locally delivered placebo gel, is associated with greater reduction in PI, mSBI, and @entity92 as well as more gain in CAL in @entity1 with @entity6 and @entity7278 .

title: Adjunctive Local Delivery of Aloe Vera Gel in @entity1 With Type 2 Diabetes and XXXX : A Randomized, Controlled Clinical Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity92 :: ('MESH:D007222', 'Disease') :: ['PD', 'probing depth']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['T2DM', 'type 2 diabetes mellitus']

entities_list: @entity7278 :: ('MESH:D055113', 'Disease') :: ['CP', 'chronic periodontitis']

answer: @entity7278 :: (MESH:D055113,Disease) :: ['Chronic Periodontitis']


abstract: BACKGROUND: Herbal agents such as Aloe vera (AV) have been used in medical and dental therapy for thousands of years. AV has anti-inflammatory, antioxidant, antimicrobial, hypoglycemic, healing-promoting, and immune-boosting properties. This study aims to investigate the clinical effectiveness of locally delivered AV gel used as an adjunct to scaling and root planing (SRP) in the treatment of @entity1 with @entity6 ( @entity6 ) and @entity7278 ( @entity7278 ). METHODS: Sixty @entity1 with @entity92 ( @entity92 ) >= 5 mm and clinical attachment level (CAL) >= 3 mm were randomly divided into two groups. All @entity1 underwent SRP. Placebo gel was locally delivered to group 1 and AV gel to group 2. Full-mouth plaque index (PI), modified sulcus bleeding index (mSBI), @entity92 , and CAL were recorded at baseline and 3 and 6 months. RESULTS: @entity1 in group 2 showed significantly greater mean reductions in PI, mSBI, and @entity92 and mean gain in CAL compared with those in group 1 from baseline to 3 months. Gain in CAL was significantly greater in group 2 at all time intervals versus group 1. CONCLUSION: Adjunctive use of locally delivered AV gel, in comparison to locally delivered placebo gel, is associated with greater reduction in PI, mSBI, and @entity92 as well as more gain in CAL in @entity1 with @entity6 and @entity7278 .

title: Adjunctive Local Delivery of Aloe Vera Gel in XXXX With Type 2 Diabetes and @entity7278 : A Randomized, Controlled Clinical Trial.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity18644 ( @entity18644 ) is a @entity2315 arising from mutations in b-d-glucuronidase ( @entity71167 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity16 . Herein, @entity18644 @entity235 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity235 @entity71167 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity71167 activity, brain tissue homogenates had only ~1 to 6% normal @entity71167 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity71167 activity 44-fold normal while brain tissue homogenates had >100% normal @entity71167 activity and reduced GAGs compared with untreated @entity235 . Markers for secondary storage and @entity32 were eliminated in i.t.-treated @entity235 and reduced in i.v.-treated @entity235 compared with untreated @entity235 . Given that i.t.-treated @entity235 expressed higher levels of @entity71167 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity18644 .

title: Evaluation of AAV-mediated Gene Therapy for Central XXXX in @entity235 @entity18644 .

entities_list: @entity2315 :: ('MESH:D016464', 'Disease') :: ['lysosomal storage disease']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disease']

entities_list: @entity18644 :: ('MESH:D016538', 'Disease') :: ['Mucopolysaccharidosis VII', 'MPS VII']

answer: @entity16 :: (MESH:D009422,Disease) :: ['Nervous System Disease']


abstract: @entity18644 ( @entity18644 ) is a @entity2315 arising from mutations in b-d-glucuronidase ( @entity71167 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity16 . Herein, @entity18644 @entity235 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity235 @entity71167 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity71167 activity, brain tissue homogenates had only ~1 to 6% normal @entity71167 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity71167 activity 44-fold normal while brain tissue homogenates had >100% normal @entity71167 activity and reduced GAGs compared with untreated @entity235 . Markers for secondary storage and @entity32 were eliminated in i.t.-treated @entity235 and reduced in i.v.-treated @entity235 compared with untreated @entity235 . Given that i.t.-treated @entity235 expressed higher levels of @entity71167 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity18644 .

title: Evaluation of AAV-mediated Gene Therapy for Central @entity16 in @entity235 XXXX .

answer: @entity18644 :: (MESH:D016538,Disease) :: ['Mucopolysaccharidosis VII']


abstract: @entity18644 ( @entity18644 ) is a @entity2315 arising from mutations in b-d-glucuronidase ( @entity71167 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity16 . Herein, @entity18644 @entity235 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity235 @entity71167 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity71167 activity, brain tissue homogenates had only ~1 to 6% normal @entity71167 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity71167 activity 44-fold normal while brain tissue homogenates had >100% normal @entity71167 activity and reduced GAGs compared with untreated @entity235 . Markers for secondary storage and @entity32 were eliminated in i.t.-treated @entity235 and reduced in i.v.-treated @entity235 compared with untreated @entity235 . Given that i.t.-treated @entity235 expressed higher levels of @entity71167 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity18644 .

title: Evaluation of AAV-mediated Gene Therapy for Central @entity16 in XXXX @entity18644 .

answer: @entity235 :: (9615,Species) :: ['Canine']


abstract: UNASSIGNED: Although supraclavicular @entity5300 (SCBPB) was repopularized by the introduction of ultrasound, its usefulness in shoulder surgery has not been widely reported. The objective of this study was to compare motor and sensory blockades, the incidence of side effects, and intraoperative opioid analgesic requirements between SCBPB and interscalene @entity5300 (ISBPB) in @entity1 undergoing arthroscopic shoulder surgery. @entity1 were randomly assigned to 1 of 2 groups (ISBPB group: n=47; SCBPB group: n=46). The side effects of the @entity5300 ( @entity4820 , hoarseness, and subjective @entity1353 ), the sensory block score (graded from 0 [no cold sensation] to 100 [intact sensation] using an @entity285 swab) for each of the 5 dermatomes (C5-C8 and T1), and the motor block score (graded from 0 [complete paralysis] to 6 [normal muscle force]) for muscle forces corresponding to the radial, ulnar, median, and musculocutaneous nerves were evaluated 20 min after the @entity5300 . @entity3575 was administered in 50  g increments when the @entity1 complained of @entity158 that was not relieved by the @entity5300 .There were no conversions to general anesthesia due to a failed @entity5300 . The sensory block scores for the C5 to C8 dermatomes were significantly lower in the ISBPB group. However, the percentage of @entity1 who received @entity3575 was comparable between the 2 groups (27.7% [ISBPB group] and 30.4% [SCBPB group], P=0.77). SCBPB produced significantly lower motor block scores for the radial, ulnar, and median nerves than did ISBPB. A significantly higher incidence of @entity4820 was observed in the ISBPB group (59.6% [ISBPB group] and 19.6% [SCBPB group], P<0.001). No @entity1 complained of subjective @entity1353 .Despite the weaker degree of sensory blockade provided by SCBPB in comparison to ISBPB, opioid analgesic requirements are similar during arthroscopic shoulder surgery under both brachial @entity616 . However, SCBPB produces a better motor blockade and a lower incidence of @entity4820 than ISBPB.

title: Comparison Between Ultrasound-Guided Supraclavicular and Interscalene Brachial Plexus Blocks in XXXX Undergoing Arthroscopic Shoulder Surgery: A Prospective, Randomized, Parallel Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity5300 :: ('MESH:D020516', 'Disease') :: ['brachial plexus block']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl', 'Fentanyl']

entities_list: @entity4820 :: ('MESH:D006732', 'Disease') :: ["Horner's syndrome"]

entities_list: @entity616 :: ('MESH:D006327', 'Disease') :: ['plexus blocks']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: Information from animal studies has demonstrated the harmful effects of @entity219 supplementation on @entity920 transport. Although some studies have been carried out in @entity1 , the effect on @entity1 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity1 and 21 @entity1 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity219 (as 220 mg @entity5937 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity920 and @entity219 . Symptoms, which included @entity10 , abdominal cramps, @entity390 , @entity1277 , were registered from 84% of @entity1 and 18% of @entity1 . Six female volunteers discontinued the trial; five owing to @entity146 and one owing to consistent @entity10 . Plasma @entity219 levels rose significantly in both @entity1 and @entity1 , the increase being 36% and 57%, respectively. Plasma @entity920 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity219 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity219 a day on plasma @entity920 levels in healthy volunteers over a period of six weeks.

title: The effect of XXXX supplements on plasma @entity219 and @entity920 levels and the reported symptoms in healthy volunteers.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'humans', 'men']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['gastric irritation']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['loss of appetite and vomiting']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches']

entities_list: @entity5937 :: ('CHEBI:35176', 'Chemical') :: ['zinc sulphate']

answer: @entity219 :: (MESH:D015032,Chemical) :: ['zinc']


abstract: Information from animal studies has demonstrated the harmful effects of @entity219 supplementation on @entity920 transport. Although some studies have been carried out in @entity1 , the effect on @entity1 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity1 and 21 @entity1 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity219 (as 220 mg @entity5937 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity920 and @entity219 . Symptoms, which included @entity10 , abdominal cramps, @entity390 , @entity1277 , were registered from 84% of @entity1 and 18% of @entity1 . Six female volunteers discontinued the trial; five owing to @entity146 and one owing to consistent @entity10 . Plasma @entity219 levels rose significantly in both @entity1 and @entity1 , the increase being 36% and 57%, respectively. Plasma @entity920 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity219 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity219 a day on plasma @entity920 levels in healthy volunteers over a period of six weeks.

title: The effect of @entity219 supplements on plasma XXXX and @entity920 levels and the reported symptoms in healthy volunteers.

answer: @entity219 :: (MESH:D015032,Chemical) :: ['zinc']


abstract: Information from animal studies has demonstrated the harmful effects of @entity219 supplementation on @entity920 transport. Although some studies have been carried out in @entity1 , the effect on @entity1 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity1 and 21 @entity1 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity219 (as 220 mg @entity5937 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity920 and @entity219 . Symptoms, which included @entity10 , abdominal cramps, @entity390 , @entity1277 , were registered from 84% of @entity1 and 18% of @entity1 . Six female volunteers discontinued the trial; five owing to @entity146 and one owing to consistent @entity10 . Plasma @entity219 levels rose significantly in both @entity1 and @entity1 , the increase being 36% and 57%, respectively. Plasma @entity920 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity219 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity219 a day on plasma @entity920 levels in healthy volunteers over a period of six weeks.

title: The effect of @entity219 supplements on plasma @entity219 and XXXX levels and the reported symptoms in healthy volunteers.

answer: @entity920 :: (MESH:D003300,Chemical) :: ['copper']


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity632 ( @entity3105 ) limits its effectiveness against @entity5 cells. @entity4447 ( @entity9188 ) has been reported to reduce MDR in various types of @entity5 , but the mechanisms involving Ras and @entity1262 ( @entity1262 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9188 in reversing MDR to @entity3105 , and to identify the association in antitumor activities between the effectiveness of @entity3105 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity1 @entity356 cell lines. @entity137 and sensitivity towards @entity9188 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9188 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity1 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9188 . The SGC7901/ADM cells were resistant to @entity3105 and @entity9188 treatment reduced the level of resistance to @entity3105 (P<0.01). The expression of @entity1262 ( @entity1262 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9188 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity1366 remained the same. @entity9188 decreased the levels of Ras and p  - @entity1366 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity1366 were further decreased (P<0.01). Drug  -resistant @entity356 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity1366 . Non  - and mildly  -toxic doses of @entity9188 reduced MDR to @entity3105 through Ras/p- @entity1366 signaling.

title: Downregulation of @entity1262 , Ras and p- @entity1366 contributes to the @entity4447 -induced reduction in drug resistance towards XXXX in @entity356 cell lines.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity4447 :: ('MESH:C006632', 'Chemical') :: ['Arsenic trioxide']

entities_list: @entity1262 :: ('5243', 'Gene') :: ['P-gp', 'P  -glycoprotein', 'p-glycoprotein']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Cytotoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity632 ( @entity3105 ) limits its effectiveness against @entity5 cells. @entity4447 ( @entity9188 ) has been reported to reduce MDR in various types of @entity5 , but the mechanisms involving Ras and @entity1262 ( @entity1262 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9188 in reversing MDR to @entity3105 , and to identify the association in antitumor activities between the effectiveness of @entity3105 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity1 @entity356 cell lines. @entity137 and sensitivity towards @entity9188 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9188 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity1 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9188 . The SGC7901/ADM cells were resistant to @entity3105 and @entity9188 treatment reduced the level of resistance to @entity3105 (P<0.01). The expression of @entity1262 ( @entity1262 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9188 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity1366 remained the same. @entity9188 decreased the levels of Ras and p  - @entity1366 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity1366 were further decreased (P<0.01). Drug  -resistant @entity356 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity1366 . Non  - and mildly  -toxic doses of @entity9188 reduced MDR to @entity3105 through Ras/p- @entity1366 signaling.

title: Downregulation of @entity1262 , Ras and p- @entity1366 contributes to the @entity4447 -induced reduction in drug resistance towards @entity632 in XXXX cell lines.

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity632 ( @entity3105 ) limits its effectiveness against @entity5 cells. @entity4447 ( @entity9188 ) has been reported to reduce MDR in various types of @entity5 , but the mechanisms involving Ras and @entity1262 ( @entity1262 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9188 in reversing MDR to @entity3105 , and to identify the association in antitumor activities between the effectiveness of @entity3105 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity1 @entity356 cell lines. @entity137 and sensitivity towards @entity9188 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9188 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity1 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9188 . The SGC7901/ADM cells were resistant to @entity3105 and @entity9188 treatment reduced the level of resistance to @entity3105 (P<0.01). The expression of @entity1262 ( @entity1262 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9188 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity1366 remained the same. @entity9188 decreased the levels of Ras and p  - @entity1366 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity1366 were further decreased (P<0.01). Drug  -resistant @entity356 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity1366 . Non  - and mildly  -toxic doses of @entity9188 reduced MDR to @entity3105 through Ras/p- @entity1366 signaling.

title: Downregulation of @entity1262 , Ras and p- XXXX contributes to the @entity4447 -induced reduction in drug resistance towards @entity632 in @entity356 cell lines.

answer: @entity1366 :: (5595;5594,Gene) :: ['ERK1/2']


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity632 ( @entity3105 ) limits its effectiveness against @entity5 cells. @entity4447 ( @entity9188 ) has been reported to reduce MDR in various types of @entity5 , but the mechanisms involving Ras and @entity1262 ( @entity1262 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9188 in reversing MDR to @entity3105 , and to identify the association in antitumor activities between the effectiveness of @entity3105 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity1 @entity356 cell lines. @entity137 and sensitivity towards @entity9188 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9188 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity1 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9188 . The SGC7901/ADM cells were resistant to @entity3105 and @entity9188 treatment reduced the level of resistance to @entity3105 (P<0.01). The expression of @entity1262 ( @entity1262 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9188 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity1366 remained the same. @entity9188 decreased the levels of Ras and p  - @entity1366 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity1366 were further decreased (P<0.01). Drug  -resistant @entity356 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity1366 . Non  - and mildly  -toxic doses of @entity9188 reduced MDR to @entity3105 through Ras/p- @entity1366 signaling.

title: Downregulation of XXXX , Ras and p- @entity1366 contributes to the @entity4447 -induced reduction in drug resistance towards @entity632 in @entity356 cell lines.

answer: @entity1262 :: (5243,Gene) :: ['P-gp']


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity632 ( @entity3105 ) limits its effectiveness against @entity5 cells. @entity4447 ( @entity9188 ) has been reported to reduce MDR in various types of @entity5 , but the mechanisms involving Ras and @entity1262 ( @entity1262 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9188 in reversing MDR to @entity3105 , and to identify the association in antitumor activities between the effectiveness of @entity3105 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity1 @entity356 cell lines. @entity137 and sensitivity towards @entity9188 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9188 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity1 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9188 . The SGC7901/ADM cells were resistant to @entity3105 and @entity9188 treatment reduced the level of resistance to @entity3105 (P<0.01). The expression of @entity1262 ( @entity1262 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9188 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity1366 remained the same. @entity9188 decreased the levels of Ras and p  - @entity1366 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity1366 were further decreased (P<0.01). Drug  -resistant @entity356 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity1366 . Non  - and mildly  -toxic doses of @entity9188 reduced MDR to @entity3105 through Ras/p- @entity1366 signaling.

title: Downregulation of @entity1262 , Ras and p- @entity1366 contributes to the XXXX -induced reduction in drug resistance towards @entity632 in @entity356 cell lines.

answer: @entity4447 :: (MESH:C006632,Chemical) :: ['arsenic trioxide']


abstract: UNASSIGNED: Over the last decades @entity56 has become a major health problem worldwide. The only specific treatment to date is @entity6542 ( @entity6542 ). Although it was shown that @entity6542 generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate @entity6542 influence on the frequency of @entity403 ( @entity403 ) Tregs in allergic @entity1 with various clinical manifestations. The relative number of @entity403 Tregs in 32 blood samples from allergic @entity1 at baseline and/or after 1 year of @entity6542 was assessed by flow cytometry. In the entire studied group, the percentage of @entity403 Tregs did not increase 1 year after @entity6542 . Nevertheless, the percentage of @entity403 Tregs after @entity6542 significantly increased in @entity1 with @entity1576 ( @entity2024 , @entity565 , and @entity2490 ) coexisting with nonrespiratory manifestations ( @entity5419 and/or @entity483 ), whereas, in @entity1 with @entity1576 only, the percentage of @entity403 Tregs decreased. To the best of our knowledge, this is the first report showing various differential @entity403 Tregs response to @entity6542 in allergic @entity1 . @entity403 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.

title: XXXX Tregs Response to Sublingual Allergen Specific Immunotherapy in @entity1 Depends on the Manifestation of Allergy.

entities_list: @entity6542 :: ('MESH:C562465', 'Disease') :: ['allergen specific immunotherapy', 'ASIT']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis']

entities_list: @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergy']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic diseases']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory allergy']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis']

answer: @entity403 :: (50943,Gene) :: ['FoxP3']


abstract: UNASSIGNED: Over the last decades @entity56 has become a major health problem worldwide. The only specific treatment to date is @entity6542 ( @entity6542 ). Although it was shown that @entity6542 generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate @entity6542 influence on the frequency of @entity403 ( @entity403 ) Tregs in allergic @entity1 with various clinical manifestations. The relative number of @entity403 Tregs in 32 blood samples from allergic @entity1 at baseline and/or after 1 year of @entity6542 was assessed by flow cytometry. In the entire studied group, the percentage of @entity403 Tregs did not increase 1 year after @entity6542 . Nevertheless, the percentage of @entity403 Tregs after @entity6542 significantly increased in @entity1 with @entity1576 ( @entity2024 , @entity565 , and @entity2490 ) coexisting with nonrespiratory manifestations ( @entity5419 and/or @entity483 ), whereas, in @entity1 with @entity1576 only, the percentage of @entity403 Tregs decreased. To the best of our knowledge, this is the first report showing various differential @entity403 Tregs response to @entity6542 in allergic @entity1 . @entity403 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.

title: @entity403 Tregs Response to Sublingual Allergen Specific Immunotherapy in XXXX Depends on the Manifestation of Allergy.

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: UNASSIGNED: @entity2213 mesylate is approved for the adjuvant treatment of KIT-positive @entity674 ( @entity674 ) following surgical resection. However, uncertainty remains in terms of @entity1 eligibility for adjuvant treatment and the optimal duration of treatment. Here, we present two challenging @entity1 cases encountered in clinical practice that highlight the ambiguity in the current recommendations for adjuvant @entity2213 in @entity674 and discuss our approaches and rationales for treatment. The first case involves a 36-year-old @entity1 with a 7   cm duodenal @entity674 and possible @entity5 rupture during surgical resection. This @entity1 's risk of @entity674 recurrence was either intermediate or high depending on which risk stratification criteria were used. The @entity1 was treated with adjuvant @entity2213 for 3 years and experienced disease recurrence 14 months after the completion of treatment. @entity2213 treatment was reintroduced, and the @entity1 is in partial response 17 months later. The second case involves a 46-year-old @entity1 at high risk of recurrence following surgical resection. Adjuvant treatment with @entity2213 was initiated. After considering the @entity1 's initial high risk and good side-effect profile, the decision was made to continue adjuvant @entity2213 treatment for 5 years. As of May 2013, the @entity1 has been receiving continuous @entity2213 treatment for 52 months, with no sign of progression. These reports exemplify the challenges faced in clinical practice because of uncertainties in optimal risk stratification criteria and duration of treatment. They stress the importance of individualized treatment and shared decision making between the physician and the @entity1 .

title: Adjuvant @entity2213 treatment in XXXX : which risk stratification criteria and for how long? A case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'man']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib']

entities_list: @entity674 :: ('MESH:D046152', 'Disease') :: ['gastrointestinal stromal tumor', 'GIST']

answer: @entity674 :: (MESH:D046152,Disease) :: ['gastrointestinal stromal tumor']


abstract: UNASSIGNED: @entity2213 mesylate is approved for the adjuvant treatment of KIT-positive @entity674 ( @entity674 ) following surgical resection. However, uncertainty remains in terms of @entity1 eligibility for adjuvant treatment and the optimal duration of treatment. Here, we present two challenging @entity1 cases encountered in clinical practice that highlight the ambiguity in the current recommendations for adjuvant @entity2213 in @entity674 and discuss our approaches and rationales for treatment. The first case involves a 36-year-old @entity1 with a 7   cm duodenal @entity674 and possible @entity5 rupture during surgical resection. This @entity1 's risk of @entity674 recurrence was either intermediate or high depending on which risk stratification criteria were used. The @entity1 was treated with adjuvant @entity2213 for 3 years and experienced disease recurrence 14 months after the completion of treatment. @entity2213 treatment was reintroduced, and the @entity1 is in partial response 17 months later. The second case involves a 46-year-old @entity1 at high risk of recurrence following surgical resection. Adjuvant treatment with @entity2213 was initiated. After considering the @entity1 's initial high risk and good side-effect profile, the decision was made to continue adjuvant @entity2213 treatment for 5 years. As of May 2013, the @entity1 has been receiving continuous @entity2213 treatment for 52 months, with no sign of progression. These reports exemplify the challenges faced in clinical practice because of uncertainties in optimal risk stratification criteria and duration of treatment. They stress the importance of individualized treatment and shared decision making between the physician and the @entity1 .

title: Adjuvant XXXX treatment in @entity674 : which risk stratification criteria and for how long? A case report.

answer: @entity2213 :: (MESH:C097613,Chemical) :: ['imatinib']


abstract: Treatment of @entity35 with toxic doses of @entity6448 ( @entity6449 ) results in reduction in feed intake, body weight, serum @entity1955 (T4) and @entity1954 (T3) concentrations, resting heart rates, and body temperatures. Some of these effects resemble changes characteristic of @entity1375 . Therefore the effects of @entity6449 on functional thyroid status were examined to relate changes in thyroid status with signs of @entity6449 @entity137 . In the present study, the dose-related effects of @entity6449 on plasma thyroid hormone concentrations and a number of indices of thyroid status were investigated and compared with signs of @entity6449 @entity137 . Young adult male @entity35 were given single intraperitoneal doses of @entity6449 (20, 40, or 80 mg/kg), and subsequent changes were evaluated 7 days after dosing. Decreases in body weight and feed intake were used as measures of @entity6449 @entity137 and ranged from minimal to severe. Plasma T4 concentrations and free thyroxine index were drastically reduced at all doses, and these changes were mimicked by pair feeding only at the high dose of @entity6449 (80 mg/kg). Plasma T3 concentrations were not affected by @entity6449 treatment, whereas pair feeding at the high-dose level (80 mg @entity6449 /kg) resulted in a significant reduction (ca. 50% from unlimited-fed control) in T3. Although @entity6449 caused a dose-dependent decrease in thyroid gland weight which was not completely paralleled by pair feeding, thyroid histology was unremarkable. @entity6449 treatment resulted in a small decrease in basal metabolic rate (8% at 80 mg @entity6449 /kg). A greater reduction (ca. 18%) in basal metabolic rate was observed in vehicle-treated controls pair-fed to @entity35 of the 80 mg @entity6449 /kg dose group. Thermogenesis, as measured by @entity26 consumption and body core temperatures, was not greatly affected by @entity6449 treatment, and these changes were paralleled by pair feeding. Reductions in plasma T4 concentration and free thyroxine index at a low dose of @entity6449 (20 mg/kg) indicate that @entity6449 -induced hypothyroxinemia can be dissociated from its overtly toxic effects (i.e., severe hypophagia and body weight loss) observed at higher doses. The results obtained here suggest that despite alterations in plasma thyroid hormone levels there is no consistent pattern of effects on functional thyroid status which could explain the overt @entity137 of @entity6449 .

title: Effects of XXXX on thyroid status in @entity35 .

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1955 :: ('MESH:D013974', 'Chemical') :: ['thyroxine']

entities_list: @entity6448 :: ('MESH:C036567', 'Chemical') :: ['perfluorodecanoic acid']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine']

answer: @entity6448 :: (MESH:C036567,Chemical) :: ['perfluorodecanoic acid']


abstract: Treatment of @entity35 with toxic doses of @entity6448 ( @entity6449 ) results in reduction in feed intake, body weight, serum @entity1955 (T4) and @entity1954 (T3) concentrations, resting heart rates, and body temperatures. Some of these effects resemble changes characteristic of @entity1375 . Therefore the effects of @entity6449 on functional thyroid status were examined to relate changes in thyroid status with signs of @entity6449 @entity137 . In the present study, the dose-related effects of @entity6449 on plasma thyroid hormone concentrations and a number of indices of thyroid status were investigated and compared with signs of @entity6449 @entity137 . Young adult male @entity35 were given single intraperitoneal doses of @entity6449 (20, 40, or 80 mg/kg), and subsequent changes were evaluated 7 days after dosing. Decreases in body weight and feed intake were used as measures of @entity6449 @entity137 and ranged from minimal to severe. Plasma T4 concentrations and free thyroxine index were drastically reduced at all doses, and these changes were mimicked by pair feeding only at the high dose of @entity6449 (80 mg/kg). Plasma T3 concentrations were not affected by @entity6449 treatment, whereas pair feeding at the high-dose level (80 mg @entity6449 /kg) resulted in a significant reduction (ca. 50% from unlimited-fed control) in T3. Although @entity6449 caused a dose-dependent decrease in thyroid gland weight which was not completely paralleled by pair feeding, thyroid histology was unremarkable. @entity6449 treatment resulted in a small decrease in basal metabolic rate (8% at 80 mg @entity6449 /kg). A greater reduction (ca. 18%) in basal metabolic rate was observed in vehicle-treated controls pair-fed to @entity35 of the 80 mg @entity6449 /kg dose group. Thermogenesis, as measured by @entity26 consumption and body core temperatures, was not greatly affected by @entity6449 treatment, and these changes were paralleled by pair feeding. Reductions in plasma T4 concentration and free thyroxine index at a low dose of @entity6449 (20 mg/kg) indicate that @entity6449 -induced hypothyroxinemia can be dissociated from its overtly toxic effects (i.e., severe hypophagia and body weight loss) observed at higher doses. The results obtained here suggest that despite alterations in plasma thyroid hormone levels there is no consistent pattern of effects on functional thyroid status which could explain the overt @entity137 of @entity6449 .

title: Effects of @entity6448 on thyroid status in XXXX .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: Due to methodologic difficulties, few investigations have been made on the blood flow velocity in the cerebral microcirculation. Using a newly developed video camera method, we simultaneously measured the blood flow velocity and diameter of pial arteries during hemorrhagic @entity551 , after blood pressure recovery, and during @entity515 inhalation in @entity468 . When the mean arterial blood pressure was lowered from 129.7 +/- 6.6 to 71.5 +/- 4.1 mm Hg, the blood flow velocity inevitably decreased from 36.6 +/- 5.3 to 27.0 +/- 3.9 mm/sec (p less than 0.001). The calculated blood flow rate [pi X (diameter/2)2 X flow velocity] was preserved in cases with concomitant vasodilation. Conversely, the blood flow velocity increased from 25.3 +/- 5.1 to 31.0 +/- 5.4 mm/sec (p less than 0.001) after mean arterial blood pressure recovery from 67.1 +/- 3.7 to 129.8 +/- 5.8 mm Hg. The blood flow rate was again preserved in vessels with a vasoconstrictive response. Each pial artery apparently dilated or constricted in proportion to the decrease or increase in flow velocity during blood pressure changes, maintaining a constant cerebral blood flow. This indicated the importance of the pial arteries in the mechanisms of cerebral blood flow autoregulation. During 5% @entity515 inhalation, the blood flow velocity increased markedly from 25.4 +/- 4.6 to 37.2 +/- 10.0 mm/sec (p less than 0.05), while the pial artery diameter (85.0 +/- 13.7 microns) increased by 9.6 +/- 1.5% (p less than 0.01). The increased flow velocity might be attributable to preferential dilatation of small arterioles or intraparenchymal vessels during @entity2944 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Quantitative measurement of blood flow velocity in feline pial arteries during hemorrhagic XXXX and @entity2944 .

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity2944 :: ('MESH:D006935', 'Disease') :: ['hypercapnia']

answer: @entity551 :: (MESH:D007022,Disease) :: ['hypotension']


abstract: Due to methodologic difficulties, few investigations have been made on the blood flow velocity in the cerebral microcirculation. Using a newly developed video camera method, we simultaneously measured the blood flow velocity and diameter of pial arteries during hemorrhagic @entity551 , after blood pressure recovery, and during @entity515 inhalation in @entity468 . When the mean arterial blood pressure was lowered from 129.7 +/- 6.6 to 71.5 +/- 4.1 mm Hg, the blood flow velocity inevitably decreased from 36.6 +/- 5.3 to 27.0 +/- 3.9 mm/sec (p less than 0.001). The calculated blood flow rate [pi X (diameter/2)2 X flow velocity] was preserved in cases with concomitant vasodilation. Conversely, the blood flow velocity increased from 25.3 +/- 5.1 to 31.0 +/- 5.4 mm/sec (p less than 0.001) after mean arterial blood pressure recovery from 67.1 +/- 3.7 to 129.8 +/- 5.8 mm Hg. The blood flow rate was again preserved in vessels with a vasoconstrictive response. Each pial artery apparently dilated or constricted in proportion to the decrease or increase in flow velocity during blood pressure changes, maintaining a constant cerebral blood flow. This indicated the importance of the pial arteries in the mechanisms of cerebral blood flow autoregulation. During 5% @entity515 inhalation, the blood flow velocity increased markedly from 25.4 +/- 4.6 to 37.2 +/- 10.0 mm/sec (p less than 0.05), while the pial artery diameter (85.0 +/- 13.7 microns) increased by 9.6 +/- 1.5% (p less than 0.01). The increased flow velocity might be attributable to preferential dilatation of small arterioles or intraparenchymal vessels during @entity2944 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Quantitative measurement of blood flow velocity in feline pial arteries during hemorrhagic @entity551 and XXXX .

answer: @entity2944 :: (MESH:D006935,Disease) :: ['hypercapnia']


abstract: BACKGROUND: We examined the hypothesis that the minimum alveolar concentration of @entity10233 for maintaining bispectral index (BIS) below 50 (MACBIS 50 ) decreases with advance of age. METHODS: Sixty young (20-30 year), middle-aged (31-65 year) and elderly (66-80 year) @entity1 were included (n = 20, each group). Five minutes following the start of continuous intravenous administration of @entity1937 at 0.25  g/kg/min, general anaesthesia was induced with @entity1875 2 mg/kg and @entity2898 0.8 mg/kg to facilitate tracheal intubation. Infusion of @entity1937 was stopped immediately after tracheal intubation. When BIS began to increase > 60, maintenance of anaesthesia was started with an end-tidal @entity10233 concentration of 4.0% and maintained for 10 min followed by 1-min assessment of BIS taken at 10-s intervals. MACBIS 50 of each age group was estimated by up-down methodology. RESULTS: MACBIS 50 of @entity10233 in young, middle-aged and elderly @entity1 was 4.25% end-tidal (95% confidence intervals 4.04-4.46), 3.58% (3.38-3.79) and 2.75% (2.50-3.00) respectively. MACBIS 50 was higher (P = 0.011) in young @entity1 and lower (P = 0.012) in elderly @entity1 than those in middle-aged @entity1 . CONCLUSIONS: Advance in age significantly decreased the concentrations of @entity10233 required to maintain BIS below 50. BIS reflected age-associated decrease in end-tidal concentrations of @entity10233 required for maintaining adequate depth of anaesthesia during resting state.

title: Age-dependent decrease in XXXX concentration for maintaining bispectral index below 50.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity10233 :: ('MESH:C053562', 'Chemical') :: ['desflurane']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

entities_list: @entity2898 :: ('MESH:C061870', 'Chemical') :: ['rocuronium']

entities_list: @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil']

answer: @entity10233 :: (MESH:C053562,Chemical) :: ['desflurane']


abstract: BACKGROUND: The purpose of this study was to determine the one-year mortality rate and its predictors regarding long-term intensive care-treated @entity1 together with their health-related quality of life (HRQL), place of living, healthcare use and long-term complication characteristics after @entity1213 ( @entity1213 ) discharge. METHODS: A retrospective cohort study was performed in a 20-bed mixed @entity1213 . The @entity1 that were treated for more than 72  h between 2007 and 2012 were included in this study. The one-year mortality rate was calculated, and the characteristics of the @entity1213 survivors that died within one year after @entity1213 discharge were further analysed. For all @entity1 , the Dutch version of the SF-36 questionnaire was used to assess their current HRQL. The results were compared with a normal population. Additionally, @entity1 were questioned about their place of living, and their general practitioners (GPs) were questioned about the @entity1 ' possible long-term complications. RESULTS: Seven hundred and forty @entity1 were included in this study, and their one-year mortality rate was 28  %, of which half died within the first week after @entity1213 discharge. The one-year mortality rate predictors included age at the time of @entity1213 admission, APACHE IV-predicted mortality score, number of comorbidities and @entity1213 re-admissions. The @entity1213 survivor HRQL was significantly lower compared with the normal population. Half of the @entity1 did not return to their pre-hospital place of living, and numerous possible long-term complications were reported, particularly decreased tolerance, chronic fatigue and processing problems of relatives. CONCLUSIONS: One-year mortality rate of long-term @entity1213 -treated @entity1 was 28  %, and this was predicted by age, disease severity, comorbidities and @entity1213 re-admissions. The @entity1213 survivors reported a lower HRQL, and a minority of these @entity1 returned home directly after hospital discharge; however, GPs reported numerous possible long-term complications.

title: Long-term treated intensive care XXXX outcomes: the one-year mortality rate, quality of life, health care use and long-term complications as reported by general practitioners.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1213 :: ('MESH:D012555', 'Disease') :: ['intensive care unit', 'ICU']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity737 is an inflammatory disease that results in the destruction of soft tissue and bone around the implant. @entity702 implant corrosion has been attributed to the implant failure and cytotoxic effects to the alveolar bone. We have documented the extent of @entity702 release into surrounding plaque in @entity1 with and without @entity737 . An in vitro model was designed to represent the actual environment of an implant in a @entity1 ' @entity2133 . The model uses actual oral microbiota from a volunteer, allows monitoring electrochemical processes generated by biofilms growing on implants and permits control of biocorrosion electrical current. As determined by next generation DNA sequencing, microbial compositions in experiments with the in vitro model were comparable with the compositions found in @entity1 with implants. It was determined that the electrical conductivity of @entity702 implants was the key factor responsible for the biocorrosion process. The interruption of the biocorrosion current resulted in a 4-5 fold reduction of corrosion. We propose a new design of dental implant that combines @entity702 in zero oxidation state for osseointegration and strength, interlaid with a nonconductive ceramic. In addition, we propose electrotherapy for manipulation of microbial biofilms and to induce @entity79 in @entity737 @entity1 .

title: Interruption of Electrical Conductivity of XXXX Dental Implants Suggests a Path Towards Elimination Of Corrosion.

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['Peri-implantitis', 'peri-implantitis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone healing']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium', 'Titanium']

answer: @entity702 :: (MESH:D014025,Chemical) :: ['Titanium']


abstract: AIM: Sympathetic overdrive is generally the main pathophysiological abnormality in @entity65 . However, its grading is not easy in clinical practice because of its complex interactions and differences in phenotypical expression. We proposed an easy, feasible, and global scaling system for sympathetic activity level. 'Sympathetic activity index' (SAI) is based on scores of heart rate, BMI, and blood pressure categories, which are the major representatives of sympathetic activity. MATERIALS AND METHODS: Respectively, 1, 2, and 3 points were determined for heart rate below 69, 70-89, and above 90   bpm; -1, 1, and 2 points for BMI less than 20, 20-24.9, and at least 25   kg/m; and 1, 2, and 3 points for normal, @entity1556 , and @entity101 categories. Demographic and echocardiographic parameters, and left ventricular (LV) mass and mass indexes (LVMIBSA and LVMIHeight) of 545 young males were compared among groups with @entity18402 -8. RESULTS: We observed that @entity10389 , LVMIBSA, and LVMIHeight, left atrial diameter were significantly increased in association with SAI (P<0.001). SAI was correlated with @entity10389 (R=0.314, P<0.001), LVMIBSA (R=193, P<0.001), and LVMIHeight (R=0.316, P<0.001). SAI of at least 5.5 could determine the left @entity123 with a sensitivity and a specificity of 57 and 70%, respectively (AUC=682, 95% confidence interval 0.610-0.753, P<0.001). CONCLUSION: Integration of clinical, anthropometric, and hemodynamic variables in a novel index such as SAI may provide an objective and noninvasive means of grading actual sympathetic drive. SAI may be used to follow-up sympathetic activity and to predict clinical events in the management of young @entity1 with @entity65 .

title: Can a novel scoring system derived from hemodynamic and anthropometric variables predict sympathetic drive in young XXXX ?

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity123 :: ('MESH:D024741', 'Disease') :: ['ventricular hypertrophy']

entities_list: @entity1556 :: ('MESH:D058246', 'Disease') :: ['prehypertension']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease', 'cardiovascular and metabolic abnormalities']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The @entity683 virus causes @entity1729 , leading to high morbidity and mortality in groups of @entity1 at higher risk. Antiviral drugs represent the first line of defense against @entity683 , both for @entity281 and pandemic outbreaks. Two main classes of drugs against @entity683 are in clinical use: M2-channel blockers and @entity689 inhibitors. Nevertheless, because @entity683 strains that are resistant to these antivirals have been described, the search for novel compounds with different mechanisms of action is necessary. Here, we investigated the anti- @entity683 activity of a fungi-derived natural product, @entity71168 . This compound inhibited @entity683 A and @entity22421 replication. This compound was more effective against @entity683 A(H3N2), with an EC50 of 100 nM. @entity71168 cytoxicity was also very low, with a CC50 value of 1426  M. @entity71168 inhibited @entity683 hemagglutination and, consequently, significantly impaired virus adsorption. Molecular modeling studies revealed that @entity71168 docked in the @entity3167 binding site of hemagglutinin, forming @entity3884 bonds with highly conserved residues. Altogether, our results indicate that the chemical structure of @entity71168 is promising for future anti- @entity683 drug design.

title: XXXX , a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin.

entities_list: @entity689 :: ('4758', 'Gene') :: ['neuraminidase']

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['sialic acid']

entities_list: @entity3884 :: ('MESH:D006859', 'Chemical') :: ['hydrogen']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['seasonal infections']

entities_list: @entity71168 :: ('MESH:C533114', 'Chemical') :: ['aureonitol', 'Aureonitol']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['acute respiratory infections']

answer: @entity71168 :: (MESH:C533114,Chemical) :: ['Aureonitol']


abstract: All @entity1 admitted from their own homes with a @entity2249 to 12 hospitals in Stockholm County Council during a three-year period were reviewed six years after the @entity174 . The outcome of the @entity174 was related to different types of treatment centers (orthopedic and surgical) and primary treatments (conservative, internal fixation, and hemiarthroplasty [HAP]). The treatment results of the four most common types of internal fixation (von Bahr, Hessel/Nystr  m, Thornton, and Rydell nails), the experience of the surgeons, and the operative delay were also compared. Of 2418 @entity1 , the majority (93%) were treated with internal fixation. Thirty-three percent of @entity1 sustained complications after conservative treatment, 37% after primary internal fixation, and 15% after primary HAP. Early redisplacement of the @entity174 was most common when the Thornton nail was used and when less experienced surgeons treated the @entity174 . Early complications such as redisplacement and nonunion occurred most often in surgical departments, but the total frequency of complications including segmental collapse was equal for different treatment centers. In surgical departments these @entity174 were operatively treated most often by less experienced surgeons and the Thornton nail was used more frequently than in orthopedic departments. An operative delay of up to one week did not result in more complications. Seventy percent of the complications after primary treatment were reoperated. Only 11% were not reoperated, either because of the presence of only minor symptoms, or because of the @entity1 's poor general condition, which made reoperation too risky. The results of the present study stress the importance of stable fixation of this @entity174 and of the experience of the surgeon for optimal treatment results.

title: Treatment and outcome of XXXX . An analysis of 2418 @entity1 admitted from their own homes.

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['femoral neck fracture']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

answer: @entity2249 :: (MESH:D005265,Disease) :: ['femoral neck fractures']


abstract: All @entity1 admitted from their own homes with a @entity2249 to 12 hospitals in Stockholm County Council during a three-year period were reviewed six years after the @entity174 . The outcome of the @entity174 was related to different types of treatment centers (orthopedic and surgical) and primary treatments (conservative, internal fixation, and hemiarthroplasty [HAP]). The treatment results of the four most common types of internal fixation (von Bahr, Hessel/Nystr  m, Thornton, and Rydell nails), the experience of the surgeons, and the operative delay were also compared. Of 2418 @entity1 , the majority (93%) were treated with internal fixation. Thirty-three percent of @entity1 sustained complications after conservative treatment, 37% after primary internal fixation, and 15% after primary HAP. Early redisplacement of the @entity174 was most common when the Thornton nail was used and when less experienced surgeons treated the @entity174 . Early complications such as redisplacement and nonunion occurred most often in surgical departments, but the total frequency of complications including segmental collapse was equal for different treatment centers. In surgical departments these @entity174 were operatively treated most often by less experienced surgeons and the Thornton nail was used more frequently than in orthopedic departments. An operative delay of up to one week did not result in more complications. Seventy percent of the complications after primary treatment were reoperated. Only 11% were not reoperated, either because of the presence of only minor symptoms, or because of the @entity1 's poor general condition, which made reoperation too risky. The results of the present study stress the importance of stable fixation of this @entity174 and of the experience of the surgeon for optimal treatment results.

title: Treatment and outcome of @entity2249 . An analysis of 2418 XXXX admitted from their own homes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The frequent and severe @entity580 in ICU @entity1 suggest that these @entity1 are immunodeficient. We studied the phagocytic activity of granulocytes and monocytes isolated from the blood of 32 ICU @entity1 with @entity55 (19 male, 13 female; age @entity19 yr). Cells were tested in standard medium and in the presence of patients' serum. Blood granulocytes and monocytes were purified and separately exposed to opsonized zymosan (to test C3 receptor function), immunoglobulin-coated erythrocytes (to test Fc receptor function), and @entity3584 -treated erythrocytes (to test nonspecific binding structures). Phagocytosis and @entity224 anion production were measured. Granulocytes of @entity1 exhibited a substantial decrease of zymosan ingestion (p less than .05), whereas phagocytosis of other particles was normal. Monocytes from the @entity1 displayed an unselective overall decrease of phagocytic ability for the three particle types (p less than .05). @entity1 ' sera were at least as efficient as a pool of normal sera in opsonizing zymosan. Further, no phagocytic inhibitor was found in the tested @entity1 . In conclusion, we point out a deficiency of membrane receptors of neutrophils and monocytes in ICU @entity1 with @entity580 .

title: Abnormalities of some phagocyte membrane receptors during XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['nosocomial pneumonia']

entities_list: @entity3584 :: ('MESH:D005976', 'Chemical') :: ['glutaraldehyde']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infection', 'nosocomial infections']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity580 :: (MESH:D003428,Disease) :: ['nosocomial infections']


abstract: A total of 250 consecutive admissions to an open-plan respiratory ICU were analyzed prospectively to identify the incidence of secondary hospital-acquired @entity281 and possible predisposing factors. Despite preventative measures and a restricted antibiotic policy, 23.6% of @entity1 developed secondary @entity281 . @entity1 admitted after multiple @entity130 were the only diagnostic category of @entity1 who showed a significantly increased incidence of secondary @entity281 . The length of hospitalization and number of @entity1 who had intubations or tracheostomies was higher in the group with @entity325 ; the causal relationship was difficult to establish. @entity1 who were not intubated or tracheostomized did not develop @entity325 . Prior administration of antibiotics did not appear to influence the incidence of @entity325 . There was a significant increase in secondary @entity281 in @entity1 with a higher therapeutic intervention scoring system score. The predominant pathogens cultured were highly resistant Gram-negative organisms, particularly Acinetobacter sp. and Pseudomonas sp. @entity794 was the most common Gram-positive pathogen. The ICU course was probably prolonged by the complication of @entity580 , which may have contributed to the @entity204 .

title: XXXX in a respiratory intensive care unit.

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['secondary infection']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infection']

answer: @entity580 :: (MESH:D003428,Disease) :: ['Nosocomial infections']


abstract: Peripheral arterial @entity1031 and @entity715 of arterial grafts continue to threaten viability of extremities. Percutaneous @entity432 ( @entity432 ) and angiodilatation have afforded limb salvage in some of these @entity1 . Proper @entity1 selection appears to be the hallmark of success with @entity432 . During a recent three-year period, we used @entity432 in 32 extremities in 28 @entity1 who had acute @entity9085 . Before @entity432 , 16 extremities were @entity158 at rest, and 16 had incapacitating @entity613 . The overall success rate was 38%, but some degree of thrombolysis occurred in 88%. Limb salvage was achieved in 27 of 32 extremities (84%). Only five of 17 limbs (29%) with arterial graft @entity715 required no operation or an operation of lesser magnitude than predicted before @entity432 . Of six extremities with native @entity1416 , four (67%) were completely cleared with @entity432 . Major complications occurred in eight cases (25%), with two @entity432 -related @entity204 (6%). This study suggests that @entity432 is best reserved for individuals with @entity63 caused by @entity2500 , those whose degree of @entity63 would tolerate a 24-hour trial of @entity432 , and those whose femoral or tibial runoff is not likely to require remedial operation.

title: Intra-arterial thrombolysis for XXXX : a three-year experience.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['acute limb ischemia', 'ischemia']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['arterial embolus']

entities_list: @entity1416 :: ('MESH:D020762', 'Disease') :: ['arterial embolism']

entities_list: @entity9085 :: ('MESH:D014715', 'Disease') :: ['arterial insufficiency']

entities_list: @entity613 :: ('MESH:D007383', 'Disease') :: ['claudication']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['intra-arterial thrombolysis', 'IAT']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity63 :: (MESH:D007511,Disease) :: ['acute limb ischemia']


abstract: Body temperature was studied in 65 @entity1 admitted to hospital within four hours of the onset of symptoms of @entity583 . Thirty three @entity1 had been randomly assigned to intravenous @entity6839 treatment and 32 to placebo treatment. @entity1188 evolution was assessed by continuous vectorcardiography and @entity908 kinase release. Maximum and mean temperatures during the first eight days were significantly lower in the @entity6839 group, who were discharged from hospital one day earlier. Eight @entity1 in the placebo group had temperatures of greater than 39 degrees compared with one in the @entity6839 group. Both the mean temperature and the maximum temperature correlated significantly with indices of @entity1188 size and ischaemic area as estimated by cumulative @entity908 kinase release, QRS vector difference, and ST vector magnitude. The results were consistent with the view that reduction of @entity1188 size may partly explain the reduced pyrexial response after @entity6839 treatment. Other mechanisms are probably also involved in larger @entity1188 . Because high fever has detrimental haemodynamic effects in @entity583 , reduction of this response may be beneficial. The results support the early use of beta adrenoceptor blockade in @entity583 .

title: Fever after @entity583 in @entity1 treated with intravenous XXXX or placebo.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['Infarct', 'infarcts', 'infarct']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

answer: @entity6839 :: (MESH:D013999,Chemical) :: ['timolol']


abstract: Body temperature was studied in 65 @entity1 admitted to hospital within four hours of the onset of symptoms of @entity583 . Thirty three @entity1 had been randomly assigned to intravenous @entity6839 treatment and 32 to placebo treatment. @entity1188 evolution was assessed by continuous vectorcardiography and @entity908 kinase release. Maximum and mean temperatures during the first eight days were significantly lower in the @entity6839 group, who were discharged from hospital one day earlier. Eight @entity1 in the placebo group had temperatures of greater than 39 degrees compared with one in the @entity6839 group. Both the mean temperature and the maximum temperature correlated significantly with indices of @entity1188 size and ischaemic area as estimated by cumulative @entity908 kinase release, QRS vector difference, and ST vector magnitude. The results were consistent with the view that reduction of @entity1188 size may partly explain the reduced pyrexial response after @entity6839 treatment. Other mechanisms are probably also involved in larger @entity1188 . Because high fever has detrimental haemodynamic effects in @entity583 , reduction of this response may be beneficial. The results support the early use of beta adrenoceptor blockade in @entity583 .

title: Fever after XXXX in @entity1 treated with intravenous @entity6839 or placebo.

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: Body temperature was studied in 65 @entity1 admitted to hospital within four hours of the onset of symptoms of @entity583 . Thirty three @entity1 had been randomly assigned to intravenous @entity6839 treatment and 32 to placebo treatment. @entity1188 evolution was assessed by continuous vectorcardiography and @entity908 kinase release. Maximum and mean temperatures during the first eight days were significantly lower in the @entity6839 group, who were discharged from hospital one day earlier. Eight @entity1 in the placebo group had temperatures of greater than 39 degrees compared with one in the @entity6839 group. Both the mean temperature and the maximum temperature correlated significantly with indices of @entity1188 size and ischaemic area as estimated by cumulative @entity908 kinase release, QRS vector difference, and ST vector magnitude. The results were consistent with the view that reduction of @entity1188 size may partly explain the reduced pyrexial response after @entity6839 treatment. Other mechanisms are probably also involved in larger @entity1188 . Because high fever has detrimental haemodynamic effects in @entity583 , reduction of this response may be beneficial. The results support the early use of beta adrenoceptor blockade in @entity583 .

title: Fever after @entity583 in XXXX treated with intravenous @entity6839 or placebo.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: STUDY DESIGN: Quasi-experimental pre-post design with 6-month follow-up. OBJECTIVES: Active Living Leaders Training Program (ALLTP) equips individuals with knowledge and skills to encourage those with @entity1566 ( @entity1566 ) to increase their leisure-time physical activity (LTPA). The purpose of this pilot study was to, first, (i) evaluate @entity1 ' perceptions of the relevance/usefulness of ALLTP material/presentation, (ii) examine changes in @entity1 ' self-efficacy to promote LTPA, (iii) identify program components associated with greater self-efficacy and, second, measure @entity1 ' use of ALLTP skills and resources over the subsequent 6 months. SETTING: Canada. METHODS: Six @entity1566 fitness trainers and six adults with @entity1566 completed the three sections of ALLTP and, after each section, provided feedback. Six months later, @entity1 ' use of resources and skills was assessed. Means, standard deviations, repeated measures analysis of variance and Pearson's correlations were computed. RESULTS: Relevance/usefulness of the program was rated favorably. Self-efficacy to speak about and encourage LTPA remained high throughout the ALLTP and was positively correlated with the relevance/usefulness of program content and presentation. At follow-up, @entity1 had discussed LTPA with an average of seven @entity1 with disabilities and reported using at least one skill and resource from the ALLTP during those discussions. CONCLUSIONS: Users had positive perceptions of ALLTP and reported using the training to promote LTPA to others with disabilities. @entity1 feedback has been used to improve ALLTP. ALLTP can now be used to train @entity1 with @entity1566 and @entity1566 fitness trainers to promote LTPA to others with disabilities.

title: Active Living Leaders Training Program for adults with XXXX : a pilot study.

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participant', 'people']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: STUDY DESIGN: Review of clinical data. OBJECTIVES: The objective of this study was to describe the clinical and demographical profile of @entity1 with @entity1566 ( @entity1566 ) admitted to a single center. SETTING: Unidad de Medicina F  sica y Rehabilitaci  n Centro, M  xico.ParticipantsPatients with @entity1566 attending rehabilitation for the first time.InterventionNot applicable.Main measurementsAge, gender, educational level, occupational activity, causes of injury, level of injury, neurological level, injury severity and category were recorded.ResultsFour hundred and sixty-four clinical files of @entity1 with @entity1566 were collected. The mean age was 37.9  15.9 years; 78.2% (363/464) were male, basic educational level predominated in 63.6% (296/464) and 73.1% (339/464) were employed. A fall was the main mechanism of the injury in 41.6% (193/464), replacing automobile accidents from the first place. The mean age of @entity1 who suffered falls was 44  16 years. Injuries sustained by younger @entity1 were due to violence (28.4  10.1 years) and the cause of injury associated with male gender was violence. Thoracic level was most often affected (in 56.7%, 263/464) and neurological level C4 in 13.4% (62/464). In regard to the extent of the injury, lesions classified as American @entity3510 Association A predominated (56.2%, 261/464) as with complete @entity451 in 43.3% (201/464).ConclusionsThe mean age of our @entity1 was 37 years. @entity1 are affected in a higher proportion. Our population has <9 years of study. Physical labor was the usual pre-injury activity. The main mechanism of injury was falls. Thoracic spine was the most affected.Spinal Cord advance online publication, 20 October 2015; doi:10.1038/sc.2015.164.

title: Clinical and demographic profile of XXXX : a mexican hospital-based study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Men', 'persons']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['TSCI', 'traumatic spinal cord injury']

entities_list: @entity3510 :: ('MESH:D013124', 'Disease') :: ['Spinal Injury']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['traumatic spinal cord injury']


abstract: UNASSIGNED: Historically, the standard approach for all mitral valve surgery has been the mediasternotomy. Although initially developed for cosmesis, minimally invasive techniques for mitral valve surgery use a limited right anterior thoracotomy with and without endoscopic techniques, which have resulted in outcomes comparable to the traditional mediasternotomy incision(1,2). Advances in robotic technology, including three dimensional visualization and improved dexterity have facilitated the introduction of robotic surgery for mitral valve repairs. In an FDA safety and efficacy trial in 2000 involving 20 @entity1 , Nifong and co-workers used robotic technology to perform a wide spectrum of mitral valve repair procedures(3). Although crossclamp and operative times were longer when compared to the conventional mediasternotomy approach, the morbidity and mortality was similar and the mean hospital length of stay (LOS) was only 4 days. A follow-up study involving 112 @entity1 showed a 30-day mortality of 0.7% and no conversions to a mediasternotomy(4). The mean hospital LOS was 5 days and the 5-year freedom from reoperation was 90%. More recent series using robotic techniques for mitral valve repairs have duplicated these excellent outcomes(5,6). Although crossclamp, cardiopulmonary bypass, and total operative times are significantly longer, there are no differences in morbidity or mortality between robotic and non-robotic repairs. In general, robotic @entity1 spend one less day in the hospital. Follow-up from 1-3 years show that > 90% of @entity1 are free of moderate-to-severe @entity339 ( @entity339 ) and the need for another mitral valve procedure. However, despite the apparent cost savings of spending one less day in the hospital, Kam and co-workers could not demonstrate any differences in hospital expenses for @entity1 undergoing robotic mitral repairs(7). The decreased LOS appears to be offset by increased operation time. Furthermore, the cost of purchasing the robotic equipment, its maintenance and need for upgrades and supplies are usually not factored into most cost analyses.

title: Robotic Mitral Valve Repair for XXXX : Is it for Everyone?

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['MR', 'mitral regurgitation']

answer: @entity339 :: (MESH:D008944,Disease) :: ['Degenerative Mitral Valve Regurgitation']


abstract: UNASSIGNED: Recent consortium guidelines support research-based screening for those at high risk of @entity788 ( @entity1124 ( @entity1124 )). Genetic testing plays an important role in the establishment of high-risk @entity1124 research clinics by delineating those individuals who would benefit from screening protocols. We retrospectively examined @entity1 referred for @entity1124 -related genetic testing from January 2009 to June 2014. @entity1 were referred for a personal and/or family history of @entity1124 or a questioned diagnosis of @entity4306 ( @entity4306 ). Of the 75 referred @entity1 , 36 underwent testing, of which 11 (31%) were mutation-positive. In total, 36% of @entity1 with @entity1689 carried a mutation, 11% of @entity1 with a family history of @entity1124 carried a mutation, and 20% of @entity1 with a personal history of @entity1124 carried a mutation. The most common barrier to testing was lack of insurance coverage. Genetic testing yields a suitable number of mutation-positive individuals who may benefit from increased screening. Subjects with possible @entity4306 yielded the highest positive rate. Individuals with @entity788 , onset of @entity788 before the age of 30 years, and those with a family history of @entity1124 should be considered for testing. Sub-optimal insurance coverage remains a major deterrent to obtaining testing.

title: Identification of genetic risk for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'pancreatic cancer', 'idiopathic pancreatitis']

entities_list: @entity1124 :: ('MESH:D021441', 'Disease') :: ['PDAC', 'pancreatic ductal adenocarcinoma']

entities_list: @entity1689 :: ('MESH:D050500', 'Disease') :: ['chronic pancreatitis']

entities_list: @entity4306 :: ('MESH:C537262', 'Disease') :: ['hereditary pancreatitis', 'HP']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']


abstract: OBJECTIVES: The study sought to examine the relative importance of lesion location versus vessel area and plaque burden in predicting @entity397 within nonculprit @entity1856 ( @entity1856 ) in @entity1 with @entity1187 . BACKGROUND: Previous studies have demonstrated that @entity397 is associated with larger vessel area and greater plaque burden clustering in the proximal segments of coronary arteries. METHODS: In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study 3-vessel grayscale and radiofrequency-intravascular ultrasound was performed after successful percutaneous coronary intervention in 697 @entity1 with @entity1187 . Untreated nonculprit lesion @entity1856 were classified as proximal (<20  mm), mid (20 to 40 mm), and distal (>40 mm) according to the distance from the ostium to the maximum necrotic core  site. RESULTS: Overall, 74 ruptured @entity1856 and 2,396 nonruptured @entity1856 were identified in nonculprit vessels. The majority of @entity1856 (73.6%) were located within 40 mm of the ostium, and the vessel area and plaque burden progressively decreased from proximal to distal FA location (both p  < 0.001). In a multivariate logistic regression model, independent predictors for  @entity397 included the distance from the ostium to the maximum necrotic core site per millimeter (odds ratio [OR]: 0.86; 95%  confidence interval [CI]: 0.76 to 0.98; p  = 0.02), plaque burden per 10% (OR: 2.05; 95% CI: 1.63 to  2.58; p  <  0.0001), vessel area per mm(2) (OR: 1.14; 95% CI: 1.11 to 1.17; p  < 0.0001), @entity460 (OR: 0.09; 95% CI: 0.05 to 0.18; p  <  0.0001), and  right coronary artery location (OR: 2.16; 95% CI: 1.25 to 3.27; p  = 0.006). By receiver-operating characteristic analysis, vessel area correlated with @entity397 stronger than either plaque burden (p  <  0.001) or location (p  < 0.001). CONCLUSIONS: Large vessel area, plaque burden, proximal location, right coronary artery location, and lack of @entity460 were associated with @entity397 . The present study suggests that among these variables, vessel area may be the strongest predictor of @entity397 among non-left main coronary arteries. ( PROSPECT: An Imaging Study in @entity1 With Unstable Atherosclerotic Lesions [PROSPECT]; NCT00180466).

title: Predictors of Plaque Rupture Within Nonculprit XXXX in @entity1 With Acute Coronary Syndromes: The PROSPECT Study.

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['FA plaque rupture', 'plaque rupture']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1856 :: ('MESH:D058226', 'Disease') :: ['FAs', 'fibroatheromas']

answer: @entity1856 :: (MESH:D058226,Disease) :: ['Fibroatheromas']


abstract: OBJECTIVES: The study sought to examine the relative importance of lesion location versus vessel area and plaque burden in predicting @entity397 within nonculprit @entity1856 ( @entity1856 ) in @entity1 with @entity1187 . BACKGROUND: Previous studies have demonstrated that @entity397 is associated with larger vessel area and greater plaque burden clustering in the proximal segments of coronary arteries. METHODS: In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study 3-vessel grayscale and radiofrequency-intravascular ultrasound was performed after successful percutaneous coronary intervention in 697 @entity1 with @entity1187 . Untreated nonculprit lesion @entity1856 were classified as proximal (<20  mm), mid (20 to 40 mm), and distal (>40 mm) according to the distance from the ostium to the maximum necrotic core  site. RESULTS: Overall, 74 ruptured @entity1856 and 2,396 nonruptured @entity1856 were identified in nonculprit vessels. The majority of @entity1856 (73.6%) were located within 40 mm of the ostium, and the vessel area and plaque burden progressively decreased from proximal to distal FA location (both p  < 0.001). In a multivariate logistic regression model, independent predictors for  @entity397 included the distance from the ostium to the maximum necrotic core site per millimeter (odds ratio [OR]: 0.86; 95%  confidence interval [CI]: 0.76 to 0.98; p  = 0.02), plaque burden per 10% (OR: 2.05; 95% CI: 1.63 to  2.58; p  <  0.0001), vessel area per mm(2) (OR: 1.14; 95% CI: 1.11 to 1.17; p  < 0.0001), @entity460 (OR: 0.09; 95% CI: 0.05 to 0.18; p  <  0.0001), and  right coronary artery location (OR: 2.16; 95% CI: 1.25 to 3.27; p  = 0.006). By receiver-operating characteristic analysis, vessel area correlated with @entity397 stronger than either plaque burden (p  <  0.001) or location (p  < 0.001). CONCLUSIONS: Large vessel area, plaque burden, proximal location, right coronary artery location, and lack of @entity460 were associated with @entity397 . The present study suggests that among these variables, vessel area may be the strongest predictor of @entity397 among non-left main coronary arteries. ( PROSPECT: An Imaging Study in @entity1 With Unstable Atherosclerotic Lesions [PROSPECT]; NCT00180466).

title: Predictors of Plaque Rupture Within Nonculprit @entity1856 in XXXX With Acute Coronary Syndromes: The PROSPECT Study.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity14407 is an @entity8304 derivative which possesses a broad spectrum antimycotic activity, including activity against @entity5132 . Its therapeutic activity and tolerability have been evaluated, in a double-blind clinical trial versus @entity1449 , in 54 @entity1 affected by mycologically confirmed symptomatic @entity365 . Both drugs were administered intravaginally as a cream once a day for 7 days. Assessment was by laboratory mycological investigations and symptomatic evaluation. @entity1 'cured' at the end of the trial were re-evaluated after 4-6 weeks for possible relapses. Both treatments resulted in a progressive, statistically significant @entity304 (itching and discharge) and in elimination of Candida in more than 95% of @entity1 . When 'cured' @entity1 were reassessed 4-6 weeks after therapy, relapses occurred in four @entity1 after @entity14407 treatment, but in none following @entity1449 treatment. This apparent difference between treatments is far from being statistically significant and, therefore, may have been a chance occurrence. It should also be noted that @entity1 from the @entity14407 group had a previous history of significantly more frequent episodes of @entity7553 suggesting that they may have been at greater risk of re-infection than @entity1 from the control group. The tolerance of both treatments was excellent since no local or systemic signs or symptoms of @entity137 were reported. An equally high efficacy and safety for both drugs in the elimination of symptoms and objective evidence of @entity365 is indicated.

title: Effect of @entity14407 in @entity365 : a double-blind clinical trial versus XXXX .

entities_list: @entity1449 :: ('MESH:D003022', 'Chemical') :: ['clotrimazole']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['reduction in vaginal symptoms']

entities_list: @entity8304 :: ('MESH:C029899', 'Chemical') :: ['imidazole']

entities_list: @entity7553 :: ('MESH:D002177', 'Disease') :: ['candidiasis']

entities_list: @entity14407 :: ('MESH:C033486', 'Chemical') :: ['fenticonazole', 'Fenticonazole']

entities_list: @entity5132 :: ('5476', 'Species') :: ['Candida albicans']

entities_list: @entity365 :: ('MESH:D014627', 'Disease') :: ['vaginal candidiasis']

answer: @entity1449 :: (MESH:D003022,Chemical) :: ['clotrimazole']


abstract: @entity14407 is an @entity8304 derivative which possesses a broad spectrum antimycotic activity, including activity against @entity5132 . Its therapeutic activity and tolerability have been evaluated, in a double-blind clinical trial versus @entity1449 , in 54 @entity1 affected by mycologically confirmed symptomatic @entity365 . Both drugs were administered intravaginally as a cream once a day for 7 days. Assessment was by laboratory mycological investigations and symptomatic evaluation. @entity1 'cured' at the end of the trial were re-evaluated after 4-6 weeks for possible relapses. Both treatments resulted in a progressive, statistically significant @entity304 (itching and discharge) and in elimination of Candida in more than 95% of @entity1 . When 'cured' @entity1 were reassessed 4-6 weeks after therapy, relapses occurred in four @entity1 after @entity14407 treatment, but in none following @entity1449 treatment. This apparent difference between treatments is far from being statistically significant and, therefore, may have been a chance occurrence. It should also be noted that @entity1 from the @entity14407 group had a previous history of significantly more frequent episodes of @entity7553 suggesting that they may have been at greater risk of re-infection than @entity1 from the control group. The tolerance of both treatments was excellent since no local or systemic signs or symptoms of @entity137 were reported. An equally high efficacy and safety for both drugs in the elimination of symptoms and objective evidence of @entity365 is indicated.

title: Effect of @entity14407 in XXXX : a double-blind clinical trial versus @entity1449 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

answer: @entity365 :: (MESH:D014627,Disease) :: ['vaginal candidiasis']


abstract: @entity14407 is an @entity8304 derivative which possesses a broad spectrum antimycotic activity, including activity against @entity5132 . Its therapeutic activity and tolerability have been evaluated, in a double-blind clinical trial versus @entity1449 , in 54 @entity1 affected by mycologically confirmed symptomatic @entity365 . Both drugs were administered intravaginally as a cream once a day for 7 days. Assessment was by laboratory mycological investigations and symptomatic evaluation. @entity1 'cured' at the end of the trial were re-evaluated after 4-6 weeks for possible relapses. Both treatments resulted in a progressive, statistically significant @entity304 (itching and discharge) and in elimination of Candida in more than 95% of @entity1 . When 'cured' @entity1 were reassessed 4-6 weeks after therapy, relapses occurred in four @entity1 after @entity14407 treatment, but in none following @entity1449 treatment. This apparent difference between treatments is far from being statistically significant and, therefore, may have been a chance occurrence. It should also be noted that @entity1 from the @entity14407 group had a previous history of significantly more frequent episodes of @entity7553 suggesting that they may have been at greater risk of re-infection than @entity1 from the control group. The tolerance of both treatments was excellent since no local or systemic signs or symptoms of @entity137 were reported. An equally high efficacy and safety for both drugs in the elimination of symptoms and objective evidence of @entity365 is indicated.

title: Effect of XXXX in @entity365 : a double-blind clinical trial versus @entity1449 .

answer: @entity14407 :: (MESH:C033486,Chemical) :: ['fenticonazole']


abstract: Between 1979 and 1985 a total of 8641 @entity1 were born at the gynecological clinic in Winterthur, 388 of them (4.5%) from breech presentation. All of these were evaluated with regard to external version, and conditions for an attempt at version were satisfied in 97 cases. The principal prerequisite was a gestational age of at least 37 weeks. External version was accomplished in 39 of the 97 cases (40.2%). Complications encountered were drops in fetal heart tone or @entity1168 in 26 cases (26.8%); the attempt at version was abandoned for this reason in 22 cases. In one case premature detachment of the normally implanted placenta occurred 6 days after successful external version, and in one case an emergency cesarean section had to be performed owing to persistent @entity1168 . In a further case @entity5617 was established 18 hours after successful version on the basis of an absence of fetal movement, though no cause of @entity204 could be found. Among the 39 cases in which version was successful a cesarean section was only necessary in one (2.5%), as opposed to 21 in the 58 cases (36.2%) in which the attempt at version failed. Neonatal fetal condition (Apgar score and umbilical blood gas analysis) revealed that neonates born from vertex presentation are subject to very considerably less stress. The international literature is discussed and compared. It is found that there has been a change of trend from a tendency to reject external version in the 1970s to a majority favoring it in the 1980s.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [External version of breech presentation--a possibility for lowering the rate of cesarean section and XXXX morbidity].

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia', 'bradycardias']

entities_list: @entity5617 :: ('MESH:D005313', 'Disease') :: ['intrauterine fetal death']

answer: @entity1 :: (9606,Species) :: ['infant']


abstract: Multipotent mesenchymal stem cells (MSCs) are recently found to alter the @entity5 condition. However their exact role in @entity5 development is not yet fully unraveled. MSCs were established to perform many of their actions through paracrine effect. Thus investigation of MSC secretome interaction with @entity5 cells may provide important information for scientists who are attempting to apply stem cells in the treatment of the disease. In this study we investigated the effect of @entity1 Wharton's jelly derived MSC (WJ-MSCs) secretome on proliferation, apoptotic potential of A549 @entity2 cells, and their response to the chemotherapeutic agent @entity632 . WJ-MSCs were isolated from @entity1 umbilical cord and then characterized according to the International Society for Cellular Therapy criteria and WJ-MSC secretome was collected. @entity1603 cell proliferation assay and @entity4404 -PI staining were used for the evaluation of cytotoxic and proapoptotic effects of WJ-MSC secretome on A549 cells. WJ-MSC secretome neither induced @entity2 cells nor affected the apoptotic potential of the @entity5 cells. We also studied the combinatorial effect of WJ-MSC secretome and the anticancer drug doxorubicinwhich showed no induction of drug resistance when A549 cells was treated with combination of WJ-MSC secretome and @entity632 . Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make @entity2 cells resistant to @entity632 . Thus MSC secretome could be considered safe for other medical purposes such as cardiovascular, neurodegenerative, and @entity792 which may exist or occur in @entity5 @entity1 .

title: Effect of @entity1 Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of XXXX cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['proliferation of lung cancer', 'lung cancer']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']